A Randomized Clinical Study On Dyslipidaemia and Comparative Evaluation Of Unani Formulation With Rosuvastatin In Its Management

Disorders of lipoprotein metabolism are collectively referred to as “dyslipidaemia.”Dyslipidaemias are generally characterized clinically by increased plasma levels of cholesterol, triglycerides, or both, variably accompanied by reduced levels of HDL cholesterol. The majority of patients with dyslipidemia have some combination of genetic predisposition (often polygenic) and environmental contribution (lifestyle, medical condition or drug).Increased levels of LDL cholesterol, remnant lipoproteins as well as decreased levels of HDL cholesterol have all been associated with an increased risk of premature vascular disease. Statins are considered first-line treatment for patients with dyslipidemia. Therapeutic benefits include plaque stabilization, improvement of coronary endothelial function,

inhibition of platelet thrombus formation, and anti-inflammatory activity. Adverse effects includes hepatotoxicity (dose related) with increase in serum transaminaselevels, headache, sleep disturbances, Myopathy- muscle pain & weakness with raisedplasma creatinine kinase activity, gastrointestinal- anorexia, nausea vomiting &diarrhoea.More serious adverse events are rare, but include rhabdomyolysis, hepatitis and

angioedema.The management of Saman-e-Mufrit is strenuous exercise, avoidance of fatty diet, excess use of vinegar, dalak-e-sulb, Hammam and specific drugs those have property to

reduce the weight. Unani system of medicine possess a large number of single and compound drugs, which are being used in the treatment of Saman-e-Mufrit like Muqil, LukMaghsool, Marzanjosh etc. To provide effective and safe treatment through Unani Medicine in Dyslipidemia, present study has been designed to validate the efficacy and safety of “Unani Formulation”which has been described in the well known unani pharmacopeia Byaz-e-khas.